Surmodics (SRDX)
(Delayed Data from NSDQ)
$39.12 USD
-0.22 (-0.56%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $39.14 +0.02 (0.05%) 7:30 PM ET
2-Buy of 5 2
C Value B Growth D Momentum C VGM
- YR Estimate
- 09/30/2023
- 09/30/2022
- 09/30/2021
- 09/30/2020
- 09/30/2019
- Revenue - Line of Business (LOBR)
- Revenue: Product sales
- 60.61
- 54.62
- 46.48
- 44.32
- 40.22
- Revenue - Line of Business (LOBR)
- Revenue: Royalties and license fees
- 62.40
- 36.25
- 47.06
- 40.63
- 48.46
- Revenue - Line of Business (LOBR)
- Revenue: Research, development and other
- 9.57
- 9.08
- 11.60
- 9.91
- 11.40
- Revenue - Line of Business (LOBR)
- Revenue: Medical Device: Product sales
- 34.13
- 27.93
- 21.78
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Medical Device: Royalties & license fees - performance coatings
- 32.81
- 30.55
- 30.78
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Medical Device: License fees - SurVeil DCB
- 29.59
- 5.70
- 16.28
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Medical Device: R&D and other
- 9.26
- 8.21
- 9.42
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Medical Device
- 105.78
- 72.39
- 78.25
- 71.40
- 78.35
- Revenue - Line of Business (LOBR)
- Revenue: In Vitro Diagnostics: Product sales
- 26.49
- 26.69
- 24.70
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: In Vitro Diagnostics
- 26.80
- 27.56
- 26.88
- 23.46
- 21.72
- Income - Line of Business (LOBI)
- Operating income (loss): Medical Device
- 5.08
- -22.92
- 4.68
- --
- --
- Income - Line of Business (LOBI)
- Operating income (loss): In Vitro Diagnostics
- 12.64
- 13.07
- 13.77
- --
- --
- Income - Line of Business (LOBI)
- Operating income (loss): Corporate
- -12.57
- -12.25
- -11.75
- --
- --